危重病危险因子非对称性二甲基精氨酸体内表达的临床意义

Clinical significance of asymmetric dimethylarginine（ADMA） as a novel risk factor for critically ill patients

非对称性二甲基精氨酸（ADMA）是一种内源性一氧化氮合酶抑制剂，与内皮功能不全密切相关，尤其在急性心血管事件、脏器功能衰竭等危重病疾患者体内中表达水平较高，目前被认为是一个新的急危重疾病的危险因子，正受到人们广泛关注。现就体内ADMA表达水平对预测急性心血管事件和危重病发生、发展及转归的临床意义作一综述。

Asymmetric dimethylarginine（ADMA） is an endogenous inhibitor of nitric oxide synthase （NOS）. Clinical studies have indicated that asymmetric dimethylarginine is closely correlated with endothelial dysfunction in various diseases , especially plasma ADMA concentration increases in acute cardiovascular effects （ACEs） and organs failure, and ADMA is a novel risk factor for critically ill patients. This review will focus on the clinical significance of raised plasma ADMA in ACEs and critically diseases.